Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET Study

Background. Sofosbuvir (SOF) is active against all hepatitis C virus (HCV) genotypes, and SOF-based therapies lead to high rates of sustained virologic response (SVR). However, genotype 3 (GT3) HCV remains a challenge with lower SVR rates reported, particularly in patients with cirrhosis. This study...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical infectious diseases 2016-09, Vol.63 (6), p.776-783
Hauptverfasser:	Feld, Jordan J., Maan, Raoel, Zeuzem, Stefan, Kuo, Alexander, Nelson, David R., Di Bisceglie, Adrian M., Manns, Michael P., Sherman, Ken, Frazier, Lynn M., Sterling, Richard, Mailliard, Mark, Schmidt, Monica, Akushevich, Lucy, Vainorius, Monika, Fried, Michael W.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged and Commentaries Antiviral Agents - adverse effects Antiviral Agents - therapeutic use ARTICLES AND COMMENTARIES Clinical medicine Drug therapy Female Genotype Genotype & phenotype Hepacivirus Hepatitis Hepatitis C virus Hepatitis C, Chronic - drug therapy Hepatitis C, Chronic - epidemiology Hepatitis C, Chronic - virology Humans Liver cirrhosis Male Middle Aged Pharmacology Prospective Studies Ribavirin - adverse effects Ribavirin - therapeutic use Sofosbuvir - adverse effects Sofosbuvir - therapeutic use Sustained Virologic Response Virology Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!